AS & Th17/IL17

Mechanistic rationales for targeting interleukin-17A in spondyloarthritis

The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features.…

IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis

The meeting was opened by Prof Atul Deodhar who introduced the prevalence, epidemiology, and clinical features of axial spondyloarthritis (axSpA), and discussed the ongoing unmet needs in the management

Anti-IL17A in Axial Spondyloarthritis—Where Are We At?

Knowledge regarding the mechanisms of the IL17-IL23 pathway and its role in spondyloarthritis has been…

Ankylosing Spondylitis pathogenesis, as we currently understand it, is T-helper 17 immune response in overdrive.

This immune axis is tasked with protecting us against extracellular bacteria, rallying neutrophils to meet the task. They patrol the barriers, the vanguard of mucosal immunity. Dysbiosis is therefore a likely trigger of AS inflammation in genetically predisposed individuals.

The other major housekeeping task of Th17 is tissue repair and remodeling. Enthesis and tendon overload with damage is the other major trigger of AS. Exuberant tissue overgrowth (skin, bone) is a feature of the Spondyloarthritides (psoriasis, AS).

Clinical medicine makes more sense once we understand the basic science better.